Table 5.
Distribution and comparison of MBL2 secretor haplotypes in cases and controls.
| Haplotypes | No. (%) of controls | No. (%) of cases | Haplotype comparison | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RVVI Cases | Clinical categories of RVVI | RVVI vs. Controls | BV vs. Controls | VVC vs. Controls | MI vs. Controls | ||||||||||
| (N = 406) | (N = 516) | BV (N = 194) | VVC (N = 124) | MI (N = 82) | OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95%CI) | p-value | |||
| HIGH SECRETOR | |||||||||||||||
| HYPA | 127 (31.3) | 163 (31.5) | 73 (37.6) | 40 (32.2) | 26 (31.7) | 1 | 1 | 1 | 1 | ||||||
| LYPA | 46 (11.2) | 44 (8.43) | 14 (7.21) | 16 (12.9) | 7 (8.5) | 0.74 (0.464–1.19) | 0.22 | 0.52 (0.27–1.02) | 0.06 | 1.10 (0.56–2.15) | 0.77 | 0.74 (0.30–1.82) | 0.51 | ||
| LYQA | 1 (0.24) | 1 (0.19) | 1 (0.5) | 0 | 0 | 0.77 (0.04–12.57) | 0.86 | 1.73 (0.10–28.23) | 0.69 | – | NA | – | NA | ||
| HYQA† | 1 (0.24) | 1 (0.19) | 1 (0.5) | 0 | 0 | 0.77 (0.04–12.57) | 0.86 | 1.73 (0.10–28.23) | 0.69 | – | NA | – | NA | ||
| LOW SECRETOR | |||||||||||||||
| LXPA | 14 (3.45) | 19 (3.71) | 3 (1.54) | 3 (2.41) | 1 (1.2) | 1.05 (0.51–2.19) | 0.88 | 0.37 (0.10–1.34) | 0.13 | 0.68 (0.18–2.48) | 0.56 | 0.34 (0.04–2.77) | 0.31 | ||
| HXPA† | 12 (3) | 31 (6.1) | 6 (3.0) | 3 (2.41) | 7 (8.5) | 2.01 (0.99–4.07) | 0.05* | 0.86 (0.31–2.41) | 0.78 | 0.79 (0.21–2.95) | 0.73 | 2.84 (1.02–7.92) | 0.04* | ||
| LYPB | 1 (0.24) | 2 (0.38) | 0 (0) | 0 | 2 (2.4) | 1.55 (0.13–17.37) | 0.71 | – | NA | – | NA | – | NA | ||
| LYQB† | 96 (23.48) | 72 (14) | 15 (7.73) | 19 (15.3) | 9 (10.9) | 0.58 (0.39–0.85) | 0.006** | 0.27 (0.14–0.50) | 0.0001*** | 0.62 (0.34–1.15) | 0.13 | 0.45 (0.20–1.02) | 0.05* | ||
| HYPB† | 0 | 1 (0.19) | 0 (0) | 0 | 0 (0) | – | NA | – | NA | – | NA | – | NA | ||
| HYQB† | 19 (4.63) | 16 (3.1) | 7 (3.6) | 2 (1.6) | 1 (1.2) | 0.65 (0.32–1.32) | 0.24 | 0.64 (0.25–1.59) | 0.33 | 0.33 (0.07–1.49) | 0.15 | 0.25 (0.03–2.00) | 0.19 | ||
| LXPB† | 0 | 2 (0.38) | 0 (0) | 1 (0.8) | 1 (1.2) | – | Na | – | NA | – | NA | – | NA | ||
| LXQB† | 79 (19.6) | 146 (28.2) | 67 (34.5) | 36 (29) | 26 (31.7) | 1.43 (1.00–2.06) | 0.04* | 1.47 (0.95–2.27) | 0.07 | 1.44 (0.85–2.45) | 0.17 | 1.60 (0.87–2.96) | 0.12 | ||
| HXQB† | 10 (2.41) | 17 (3.3) | 7 (3.6) | 4 (3.2) | 1 (1.2) | 1.32 (0.58–2.99) | 0.4990 | 1.21 (0.44–3.33) | 0.70 | 1.27 (0.37–4.27) | 0.69 | 0.48 (0.05–3.98) | 0.50 | ||
| HXPB† | 0 | 1 (0.19) | 0 | 0 | 1 (1.2) | – | NA | – | NA | – | NA | – | NA | ||
| HIGH vs. LOW SECRETOR | |||||||||||||||
| High‡ | 175 (43.1) | 208 (40.3) | 89 (45.8) | 56 (45.1) | 33 (40.2) | 0.89 (0.68–1.16) | 0.3929 | 1.11 (0.79–1.57) | 0.52 | 1.08 (0.72–1.62) | 0.68 | 0.88 (0.54–1.44) | 0.63 | ||
| Low§ | 231 (56.8) | 308 (59.6) | 105 (54) | 68 (54.8) | 49 (59.7) | 1 | 1 | 1 | 1 | ||||||
Global p-value for case/control haplotype association was 0.01,
†
Novel secretor haplotypes observed in this study;
‡
High secretor MBL2* (HYPA_LYQA_LYPA_HYQA);
§
Low secretor MBL2* (LXPA_LYPB_LYQB_HYPB_HXPA_HYQB_LXPB_LXQB_HXQB_HXPB); NA, not applicable.
*
p < 0.05;
**
p < 0.01;
***
p < 0.001.
High and low secretor status of haplotypes was designated based on previous literature.